首页> 外文期刊>Rheumatology International >Comparison of trimethoprim–sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease
【24h】

Comparison of trimethoprim–sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease

机译:甲氧苄啶-磺胺甲恶唑和雾化喷他idine对预防免疫力低下的结缔组织病患者大肠杆状肺炎性肺炎的预防作用比较

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

To evaluate the efficacy of primary prophylaxis for Pneumocystis jiroveci pneumonia (PCP) in patients with connective tissue disease (CTD) and immunosuppression, we compared trimethoprim–sulfamethoxazole (TMP-SMZ) with aerosolized pentamidine. Forty-eight CTD patients of Kitasato University Hospital whose CD4+ lymphocyte count in the peripheral blood was less than 300 μl−1 were reviewed from 2002 to 2004. Twenty-seven patients received TMP–SMZ and none of them developed PCP. Among 18 patients receiving aerosolized pentamidine, three patients developed PCP. These data indicate that TMP–SMZ is better for prophylaxis than aerosolized pentamidine.
机译:为了评估对结缔组织病(CTD)和免疫抑制患者的初级肺炎支原体肺炎(PCP)预防效果,我们将甲氧苄氨嘧啶-磺胺甲基异恶唑(TMP-SMZ)与雾化喷他idine定进行了比较。 2002年至2004年对北里大学医院的48名CTD患者的外周血CD4 +淋巴细胞计数低于300μl -1 进行了回顾。27例患者接受了TMP–SMZ,但均未接受开发的PCP。在18例接受雾化喷他idine的患者中,有3例患上了PCP。这些数据表明,TMP-SMZ的预防效果优于雾化的喷他idine。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号